Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer

SIMPLE SUMMARY: HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer (BC) is an emerging subtype of BC with promising results with antibody drug conjugate (ADC) in the metastatic setting. In the early setting, few data have been reported regarding the predictive and prognostic impact of HER2-low status in...

Descripción completa

Detalles Bibliográficos
Autores principales: Domergue, Camille, Martin, Elodie, Lemarié, Camille, Jézéquel, Pascal, Frenel, Jean-Sebastien, Augereau, Paule, Campone, Mario, Patsouris, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139240/
https://www.ncbi.nlm.nih.gov/pubmed/35626113
http://dx.doi.org/10.3390/cancers14102509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139240/
https://www.ncbi.nlm.nih.gov/pubmed/35626113
http://dx.doi.org/10.3390/cancers14102509

Ejemplares similares